Nautilus Biotechnology, Inc.

NASDAQ:NAUT

Biotechnology

Healthcare
$2.43 +2.06%

+$0.05 today

Market cap
$309.51M
Beta
0.75
P/E (TTM)
-4.9
EPS (TTM)
-$0.45
52W Low $0.62High $4.31

Volume 4.55M

Average 0.40M

NAUT Total Debt

Short-term and long-term borrowings combined.

Nautilus Biotechnology, Inc.NASDAQ: NAUT

Total Debt · Q1 FY2026 · quarter ended Mar 2026

Total debt broadly unchanged from a year ago

Total debt stood at $28.87M at the end of Q1 FY2026, down 1.6% from a year earlier and down 3.8% from the prior quarter. Over 3 fiscal years it compounded at -0.3% a year.

Context

  • Total debt amounted to 16.2% of total assets at the end of Q1 FY2026, up 3.4 pp from a year earlier.
  • Total debt increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -1.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$28.87M-3.8% QoQ
Last fiscal yearDec 2025
$30.02M-1.5% YoY
Year agoMar 2025
$29.34M-1.6% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.6%——
1 year-1.5%——
3-year CAGR-0.3%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
30.02M USD
Year-over-year change
-1.5%
4-year CAGR
-0.0%

Total Debt vs competitors

How NAUT compares with its peers on the latest reported figures

  • NAUT's Mar 2026 total debt of $28.87M is the 5th highest of the 11 companies compared; the peer median is $21.12M.
  • Its year-over-year change of -1.6% is the 5th highest of 10, against a peer median of -8.0%.
  • Total debt amounts to 16.2% of total assets for NAUT, versus a peer median of 8.6%.
NAUT Competitors Peer median
Total Debt for NAUT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMRXImmuneering CorporationMar 2026$3.73B +91265.7%-7.6%1.7%
ENTAEnanta Pharmaceuticals, Inc.Mar 2026$186.62M -13.7%+96.0%59.3%
HUMAHumacyte, Inc.Mar 2026$65.9M +315.8%+9.0%59.6%
FHTXFoghorn Therapeutics Inc.Mar 2026$41.99M +20.5%-7.1%18.9%
NAUTNautilus Biotechnology, Inc.Mar 2026$28.87M -1.6%-0.3%16.2%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$23.99M -43.8%-35.9%9.8%
PYXSPyxis Oncology, Inc.Mar 2026$18.26M -8.0%-0.4%28.4%
TNYATenaya Therapeutics, Inc.Mar 2026$10.12M -21.6%-10.5%7.5%
ASMBAssembly Biosciences, Inc.Mar 2026$2.49M -17.5%-8.8%1.1%
SGMTSagimet Biosciences Inc.Mar 2026$39K +0.0%-28.2%0.0%
ZURAZura Bio LimitedMar 2026$0 ——0.0%
Peer median (excluding NAUT) $21.12M-8.0%-7.6%8.6%

Competitors are the stored peer set for NAUT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents185.62M114.52M19.4M27.65M12.39M
Short-term Investments160.11M69.95M154.02M102.25M91.02M
Net Receivables00000
Inventory00000
Other Current Assets003.42M2.93M2.56M
Total Current Assets349.22M187.21M176.84M132.83M105.96M
Property, Plant & Equipment (Net)31.86M32.57M36.9M32.33M31.23M
Goodwill00000
Intangible Assets00000
Long-term Investments16.37M129.17M90.65M76.41M52.74M
Tax Assets00000
Other Non-current Assets997K1.11M1.18M1.18M1.18M
Total Non-current Assets49.23M162.84M128.73M109.92M85.15M
Total Assets398.45M350.05M305.57M242.74M191.11M
Account Payables1.72M1.27M1.64M987K943K
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities388K438K2.97M1.86M2.7M
Total Current Liabilities5.81M6.79M9.12M7.63M7.95M
Long-term Debt000026.19M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities29.06M28.34M31.09M26.38M26.19M
Total Liabilities34.87M35.13M40.21M34.01M34.14M
Common Stock12K12K13K13K13K
Retained Earnings(80.64M)(138.56M)(202.24M)(273.02M)(332.02M)
Accumulated OCI(184K)(1.85M)(255K)57K243K
Other Stockholders Equity(0)0000
Minority Interest00000
Total Equity363.58M314.92M265.35M208.73M156.97M
Total Debt30.03M30.33M34.63M30.48M30.02M
Net Debt(155.59M)(84.2M)15.23M2.83M17.63M

Nautilus Biotechnology, Inc.

NASDAQ:NAUT

Intrinsic Alpha fair value

Locked

Current Price

$2.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.